Pfizer, Metabomed deal receives competition exemption in Israel
MLex Summary: Israel’s Antitrust Authority has cleared Pfizer’s planned investment in cancer metabolism drug company Metabomed. Pfizer will acquire a 15.91 percent stake in exchange for capital investment. Previous investors in Metabomed...To view the full article, register now.
Already a subscriber? Click here to view full article